Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismBacteria replacements [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot ApplicableIIT Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria:a Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study
This is a randomized, double-blind, placebo-controlled, parallel-group study. A total of 15 children with phenylketonuria(PKU) age 3 to 17 years will be randomized to two groups. Experimental group of 10 children will intervene engineered probiotics (CBT102-A) for 20 days and 5 children will intervene placebo. The goal of this study is to determine whether CBT102-A is an effective and safe treatment for PKU.
100 Clinical Results associated with Hedu Biotechnology (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Hedu Biotechnology (Shanghai) Co., Ltd.
100 Deals associated with Hedu Biotechnology (Shanghai) Co., Ltd.
100 Translational Medicine associated with Hedu Biotechnology (Shanghai) Co., Ltd.